XM does not provide services to residents of the United States of America.
E
E

EMS

Trade Ideas

Traders Sentiment

Technical Summary

Hourly

News

Arkema, Fuller Smith & Turner, Siemens Energy

EUROPE RESEARCH ROUNDUP- Arkema, Fuller Smith & Turner, Siemens Energy May 9 (Reuters) - Securities analysts revised their ratings and price targets on several European companies, including Arkema, Fuller Smith & Turner and Siemens Energy, on Thursday. HIGHLIGHTS * Arkema SA AKE.PA : HSBC raises target price to EUR 117 from EUR 107 * Bytes Technology Group Plc BYIT.L : Deutsche Bank initiates coverage with buy rating * Fuller Smith & Turner Plc FSTA.L : Deutsche Bank initiates coverage with buy
A
A
A
A
B
B
B
B
C
E
E
G
A
A
B
D
G

Swiss EMS Chemie's sales slip on depressed demand and higher costs

UPDATE 1-Swiss EMS Chemie's sales slip on depressed demand and higher costs Adds currency impact in paragraph 2, analyst comments in 3 April 25 (Reuters) - Swiss nylon manufacturer EMS Chemie EMSN.S reported an 11% drop in first-quarter net sales on depressed consumer demand and lingering high raw material and freight costs, it said on Thursday, while confirming its 2024 forecast.
E

Swiss EMS Chemie posts 11% drop in Q1 sales on stronger Swiss franc

Swiss EMS Chemie posts 11% drop in Q1 sales on stronger Swiss franc April 25 (Reuters) - Swiss nylon manufacturer EMS Chemie EMSN.S reported a double-digit drop in first-quarter net sales as the Swiss franc's strengthening curtailed net sales development, it said on Thursday, while confirming its 2024 forecast. The Group's Q1 net sales decreased 11.3% year-on-year to 545 million Swiss Franc ($596.21 million), in line with two analysts' predictions that had projected a yearly drop in the range of
C
E

Swiss stocks - Factors to watch on April 25

Swiss stocks - Factors to watch on April 25 ZURICH/BERLIN, April 25 (Reuters) - Here are some of the main factors that may affect Swiss stocks on Thursday: UBS UBSG.S A new lawsuit by U.S. hedge fund Appaloosa LP accuses the former Credit Suisse of misleading investors about its health before $17 billion of its bonds were written down to zero in a government-orchestrated rescue by Swiss rival UBS UBSG.S.
A
C
E
N
T
U
W
T

Ems Chemie Sees 2024 EBIT Slightly Above Previous Year

BRIEF-Ems Chemie Sees 2024 EBIT Slightly Above Previous Year April 25 (Reuters) - Ems Chemie Holding AG EMSN.S : FOR THE BUSINESS YEAR 2024, EMS EXPECTS THE ECONOMIC ENVIRONMENT TO REMAIN CHALLENGING OUTLOOK: FOR 2024, EMS CONTINUES TO EXPECT NET SALES AT PREVIOUS YEAR'S LEVEL AND NET OPERATING INCOME (EBIT) SLIGHTLY ABOVE PREVIOUS YEAR ACHIEVED NE
E

Conditions

Popular Assets

Disclaimer: The XM Group entities provide execution-only service and access to our Online Trading Facility, permitting a person to view and/or use the content available on or via the website, is not intended to change or expand on this, nor does it change or expand on this. Such access and use are always subject to: (i) Terms and Conditions; (ii) Risk Warnings; and (iii) Full Disclaimer. Such content is therefore provided as no more than general information. Particularly, please be aware that the contents of our Online Trading Facility are neither a solicitation, nor an offer to enter any transactions on the financial markets. Trading on any financial market involves a significant level of risk to your capital.

All material published on our Online Trading Facility is intended for educational/informational purposes only, and does not contain – nor should it be considered as containing – financial, investment tax or trading advice and recommendations; or a record of our trading prices; or an offer of, or solicitation for, a transaction in any financial instruments; or unsolicited financial promotions to you.

Any third-party content, as well as content prepared by XM, such as: opinions, news, research, analyses, prices and other information or links to third-party sites contained on this website are provided on an “as-is” basis, as general market commentary, and do not constitute investment advice. To the extent that any content is construed as investment research, you must note and accept that the content was not intended to and has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such, it would be considered as marketing communication under the relevant laws and regulations. Please ensure that you have read and understood our Notification on Non-Independent Investment. Research and Risk Warning concerning the foregoing information, which can be accessed here.

Risk Warning: Your capital is at risk. Leveraged products may not be suitable for everyone. Please consider our Risk Disclosure.